Literature DB >> 18971924

Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months.

Andreas D Kistler1, Diane Poster, Fabienne Krauer, Dominik Weishaupt, Shagun Raina, Oliver Senn, Isabelle Binet, Katharina Spanaus, Rudolf P Wüthrich, Andreas L Serra.   

Abstract

Kidney volume growth is considered the best surrogate marker predicting the decline of renal function in autosomal dominant polycystic kidney disease. To assess the therapeutic benefit of new drugs more rapidly, changes in kidney volume need to be determined over a short time interval. Here we measured renal volume changes by manual segmentation volumetry applied to magnetic resonance imaging scans obtained with an optimized T1-weighted acquisition protocol without gadolinium-based contrast agents. One hundred young patients with autosomal dominant polycystic kidney disease and preserved renal function had a significant increase in total kidney volume by 2.71+/-4.82% in 6 months. Volume measurements were highly reproducible and accurate, as indicated by correlation coefficients of 1.000 for intra-observer and 0.996 for inter-observer agreement, with acceptable within-subject standard deviations. The change in renal volume correlated with baseline total kidney volume in all age subgroups. Total kidney volume positively correlated with male gender, hypertension, albuminuria and a history of macrohematuria but negatively with creatinine clearance. Albuminuria was associated with accelerated volume progression. Our study shows that increases in kidney volume can be reliably measured over a 6 month period in early autosomal dominant polycystic kidney disease using unenhanced magnetic resonance imaging sequences.

Entities:  

Mesh:

Year:  2008        PMID: 18971924     DOI: 10.1038/ki.2008.558

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  54 in total

Review 1.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 2.  Rationale for early treatment of polycystic kidney disease.

Authors:  Jared J Grantham
Journal:  Pediatr Nephrol       Date:  2014-07-15       Impact factor: 3.714

3.  Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease.

Authors:  Ramón Peces; Emilio Cuesta-López; Carlos Peces; Virginia Pérez-Dueñas; Cristina Vega-Cabrera; Rafael Selgas
Journal:  Int Urol Nephrol       Date:  2010-05-07       Impact factor: 2.370

4.  Distinct patterns of kidney and liver cyst growth in pkd2(WS25/-) mice.

Authors:  R Brian Doctor; Natalie J Serkova; Kendra M Hasebroock; Iram Zafar; Charles L Edelstein
Journal:  Nephrol Dial Transplant       Date:  2010-04-13       Impact factor: 5.992

5.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

6.  Evidence of extraordinary growth in the progressive enlargement of renal cysts.

Authors:  Jared J Grantham; Larry T Cook; Louis H Wetzel; Melissa A Cadnapaphornchai; Kyongtae T Bae
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-01       Impact factor: 8.237

Review 7.  Treatment strategies and clinical trial design in ADPKD.

Authors:  Vicente E Torres
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

8.  Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; James E Bost; Vicente E Torres; Lisa Guay-Woodford; Kyongtae Ty Bae; Douglas Landsittel; Jie Li; Bernard F King; Diego Martin; Louis H Wetzel; Mark E Lockhart; Peter C Harris; Marva Moxey-Mims; Mike Flessner; William M Bennett; Jared J Grantham
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-16       Impact factor: 8.237

9.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

10.  Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images.

Authors:  Timothy L Kline; Marie E Edwards; Panagiotis Korfiatis; Zeynettin Akkus; Vicente E Torres; Bradley J Erickson
Journal:  AJR Am J Roentgenol       Date:  2016-06-24       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.